查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1929535

生技藥品CXO服務市場按服務模式、治療領域、臨床階段、應用和最終用戶分類，全球預測（2026-2032年）

Biologics CXO Services Market by Service Model, Therapeutic Area, Clinical Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年生物製劑 CXO 服務市值為 5.8021 億美元，預計到 2026 年將成長至 6.2493 億美元，複合年成長率為 7.06%，到 ​​2032 年將達到 9.3584 億美元。

關鍵市場統計數據
基準年 2025 5.8021億美元
預計年份：2026年 6.2493億美元
預測年份 2032 9.3584億美元
複合年成長率 (%) 7.06%

本書簡明扼要地全面介紹了由科學創新、監管複雜性和策略外包共同塑造的、不斷發展的生物製藥合約服務生態系統。

生物製藥合約服務產業正演變為一個複雜的生態系統，科學創新、監管細則和規模經濟在此交匯融合。包括製造商、服務供應商、申辦者和研究機構在內的相關人員，正在藥物發現、開發和商業化過程中加強合作。這一趨勢正在重塑人們對外包活動的速度、品質和合規性的預期，使得合作夥伴的選擇和能力匹配具有重要的策略意義。

透過證據檢驗美國近期關稅措施對生物製藥計畫供應鏈韌性、營運成本和策略採購決策的影響。

近期貿易政策調整帶來的發展趨勢，為跨境生物製藥研發和供應機構的營運帶來了新的複雜性。關稅帶來的成本壓力在關鍵原料、一次性組件和分析試劑的運輸中尤為顯著，迫使採購團隊重新評估供應商組合，並探索能夠維持供應連續性和品質標準的替代籌資策略。同時，海關延誤可能會加劇臨床試驗啟動時間和產品上市時間的風險，尤其對於那些依賴臨床和生產基地之間緊密協調的物流的專案而言。

關鍵細分洞察揭示了服務模式專業化、治療方法、臨床階段、最終用戶類型和公司規模如何影響合作夥伴的選擇和能力要求。

深入分析市場細分，可以發現能力、專案階段和最終用戶優先級等因素交織，共同塑造了服務需求。以服務模式分析市場發現，產品和服務分佈在CDMO、CMO和CRO三大領域。 CDMO的專業技術往往集中在分析測試、生產製造、製程開發和法規諮詢方面。 CMO通常專注於臨床和商業化生產，而CRO的核心服務則包括臨床試驗管理、藥物監測和臨床前服務。這種分層服務結構凸顯了服務提供者既需要在各個技術領域展現深厚的專業知識，也需要具備支援多階段開發計畫所需的協調能力。

區域動態和能力叢集對關鍵區域的合作夥伴選擇、臨床試驗准入、監管協調和生產本地化產生影響

區域趨勢反映了人才供應、法規環境和基礎設施的差異，從而重塑了投資和夥伴關係的發生地點。在美洲，成熟的生態系統將成熟的生物製造能力與密集的臨床試驗中心網路和監管專業知識相結合，為高度複雜的項目和快速的臨床轉化提供了支持。儘管該地區仍然是創新中心，但也面臨更高的營運成本以及對熟練的生產和品管人員的激烈競爭。

對公司能力和競爭差異化趨勢的描述，闡述了技術深度、監管專業知識和綜合服務模式如何奠定市場領導地位。

在生物製劑合約服務領域，各公司之間的競爭日益取決於技術實力的深度、平台的擴充性以及在研發各階段提供整合服務的能力。主要企業透過投資先進的分析技術、模組化生產平台以及能夠應對跨國申報的法規諮詢團隊來脫穎而出。同樣重要的是品質系統和資料管治實務的完善程度，客戶要求在整個外包合作關係中保持透明的可追溯性和強大的審核能力。

為產業領導者提供切實可行的建議，以加強生物製劑專案的供應鏈韌性、加速技術能力融合併提升客戶合作

產業領導者應優先考慮增強供應鏈韌性、加速跨模式技術整合以及提升以客戶為中心的服務水準。首先，應將貿易中斷、原料短缺和監管變化等情境規劃納入採購和供應鏈管治，以降低專案脆弱性。這包括供應商多元化、建構跨區域冗餘以及規範監管溝通的變更管理流程。

嚴謹的混合調查方法結合了關鍵相關人員訪談、監管和技術文獻綜述以及三角驗證的定性分析，確保了研究結果的可靠性。

該研究採用混合方法進行綜合分析，結合了對主要相關人員的訪談、對技術和監管指南的二次審查，以及對公開文件和科學文獻的定性分析。主要工作包括與生產和臨床營運經理、品質和監管專家以及研發經理進行結構化討論，以收集第一線觀點對能力差距、投資重點和合作夥伴選擇標準的看法。此外，還對監管指導文件和同行評審的研究文章進行了重點審查，以確保技術準確性並檢驗新興趨勢。

在不斷發展的生物製劑服務環境中，對決定合作夥伴選擇和專案成功的策略重點和能力要求進行綜合分析。

總而言之，生物製藥合約服務生態系統正日趨成熟，成為一個策略性、協作性的網路，其中技術能力、監管敏銳度和供應鏈韌性決定著專案的成功。細胞和基因療法的技術進步，以及不斷變化的監管預期，正在催生對涵蓋藥物發現到商業化生產的一體化服務模式的需求。區域能力叢集和關稅相關的貿易考量正在重塑採購決策，促使企業採用更完善的風險管理和在地化策略。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章生技藥品CXO服務市場依服務模式分類

  • CDMO
    • 分析測試
    • 製造業
    • 製程開發
    • 監理諮詢
  • CMO
    • 臨床生產
    • 商業生產
  • CRO
    • 臨床試驗管理
    • 藥物安全檢測
    • 非臨床試驗服務

第9章生技藥品CXO服務市場（依治療領域分類）

  • 自體免疫疾病
  • 循環系統
  • 感染疾病
  • 神經病學
  • 腫瘤學

第10章生技藥品CXO服務市場（依臨床階段分類）

  • 商業的
  • 探勘階段
  • I期試驗
  • 第二階段
  • 第三階段
  • 臨床前

第11章生技藥品CXO服務市場（依應用領域分類）

  • 細胞療法
  • 基因治療
  • 單株抗體
  • 重組蛋白
  • 疫苗

第12章生技藥品CXO服務市場（依最終用戶分類）

  • 學術機構
  • 生物製藥公司
  • 研究所

第13章生技藥品CXO服務市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章生技藥品首席體驗長 (CXO) 服務市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國生技藥品高階主管服務市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國生技藥品首席體驗長 (CXO) 服務市場

第17章：中國生技藥品高階主管服務市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AGC Biologics
  • AGC Inc.
  • Alvotech hf.
  • BioVectra Inc.
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Curia Global, Inc.
  • Fujifilm Holdings Corporation
  • Hikma Pharmaceuticals PLC
  • Lonza Group AG
  • Merck KGaA
  • Novasep Holding SAS
  • Patheon Biologics
  • Piramal Pharma Solutions
  • Polpharma Biologics
  • PTC Bio, Inc.
  • Recipharm AB
  • Richter-Helm Biologics GmbH & Co. KG
  • Samsung Biologics Co., Ltd.
  • Sartorius AG
  • Siegfried Holding AG
  • Thermo Fisher Scientific Inc.
  • Vetter Pharma International GmbH
  • WuXi Biologics Inc.
  • Xellia Pharmaceuticals A/S
Product Code: MRR-0A3806951800

The Biologics CXO Services Market was valued at USD 580.21 million in 2025 and is projected to grow to USD 624.93 million in 2026, with a CAGR of 7.06%, reaching USD 935.84 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 580.21 million
Estimated Year [2026] USD 624.93 million
Forecast Year [2032] USD 935.84 million
CAGR (%) 7.06%

A concise yet comprehensive introduction to the evolving biologics contract services ecosystem shaped by scientific innovation, regulatory complexity, and strategic outsourcing

The biologics contract services landscape is evolving into a complex ecosystem where scientific innovation, regulatory nuance, and operational scale converge. Stakeholders including manufacturers, service providers, sponsors, and research institutions are navigating tighter integration between discovery, development, and commercialization pathways. This dynamic is reshaping expectations for speed, quality, and compliance across outsourced activities, elevating the strategic importance of partner selection and capability alignment.

As organizations pursue advanced modalities such as cell and gene therapies alongside traditional monoclonal antibodies and recombinant proteins, service providers are compelled to broaden their technical depth while maintaining rigorous quality systems. Investment decisions are increasingly influenced by the ability to support multi-phase programs, deliver analytical and process development expertise, and provide regulatory consulting that anticipates global expectations. The evolving buyer-supplier relationship emphasizes collaboration over transactional procurement, with an emphasis on co-development, IP protection, and flexible commercial models.

The industry is undergoing transformative shifts that are redefining how biologics are developed and brought to market. Technological advances in cell and gene therapies are driving demand for specialized capabilities in vector manufacturing, cell processing, and potency assays, while high-throughput analytical platforms and single-use technologies are enabling faster scale-up and reduced cross-contamination risk. Concurrently, regulatory agencies are issuing more detailed guidance on comparability, control strategies, and long-term safety monitoring, prompting service providers to invest in robust quality systems and enhanced data integrity solutions.

Commercial considerations are also in flux as sponsors seek partners capable of spanning early-stage development through commercial supply. This has incentivized consolidation and strategic partnerships across CDMOs, CMOs, and CROs to create vertically integrated offerings. Geographic diversification of supply chains is accelerating as organizations hedge regional risks and pursue proximity to clinical trial sites and manufacturing talent pools. Overall, the landscape is moving towards end-to-end service models, closer scientific collaboration, and stronger emphasis on digitalization to enable traceability, predictive maintenance, and remote oversight.

An evidence-based examination of how recent United States tariff actions are influencing supply chain resilience, operational costs, and strategic sourcing decisions across biologics programs

Recent tariff developments originating from trade policy adjustments have introduced a new layer of operational complexity for organizations engaged in cross-border biologics development and supply. Tariff-driven cost pressures are most apparent in the movement of critical raw materials, single-use components, and analytical reagents, requiring procurement teams to reassess supplier portfolios and to seek alternative sourcing strategies that preserve supply continuity and quality standards. In parallel, customs-related delays can amplify time-to-clinic and time-to-market risks for programs that depend on tightly choreographed logistics between clinical sites and manufacturing facilities.

Strategically, teams are reallocating inventory buffers and exploring regionalization of certain manufacturing steps to reduce exposure to tariff volatility and to maintain control over validated supply chains. Regulatory considerations become salient when substituting suppliers or materials, as comparability data may be needed to satisfy authorities. Service providers and sponsors are responding by strengthening contractual terms, enhancing transparency around cost pass-through mechanisms, and integrating tariff scenario planning into their risk management frameworks to safeguard program timelines and product integrity.

Key segmentation insights that reveal how service model specialization, therapeutic modality, clinical stage, end-user type, and company size drive partner selection and capability requirements

A nuanced view of segmentation reveals where capabilities, program stages, and end-user priorities intersect to shape service demand. When examining the market by service model, offerings are distributed across CDMO, CMO, and CRO frameworks; within CDMOs, specialization often clusters around analytical testing, manufacturing, process development, and regulatory consulting, while CMOs are typically focused on clinical manufacturing and commercial manufacturing, and CROs center on clinical trial management, pharmacovigilance, and preclinical services. This layered service architecture underscores the need for providers to demonstrate both depth in discrete technical domains and the orchestration skills required to support multi-phase development timelines.

Application-driven segmentation highlights modality-specific requirements. Cell therapy initiatives require end-to-end support spanning discovery through commercial supply, with critical dependencies on closed-system processing, chain-of-identity controls, and potency assays. Gene therapy programs demand vector manufacturing, delivery analytics, and long-term biodistribution studies across clinical stages. Monoclonal antibodies and recombinant proteins share a reliance on scalable upstream and downstream processes coupled with advanced analytical characterization. Vaccines present distinct cold-chain and fill-finish challenges that intersect with public health imperatives. Therapeutic area segmentation emphasizes different regulatory and clinical paradigms; oncology development pathways often prioritize accelerated timelines and biomarker-driven endpoints, whereas infectious disease programs emphasize population-scale manufacturing and global distribution considerations. Clinical-stage segmentation clarifies how needs evolve from discovery to preclinical and through phased clinical development into commercial supply, and end-user segmentation differentiates priorities among academia, biopharmaceutical companies, and research institutions. Company-size segmentation further differentiates expectations; large pharmaceutical organizations tend to require global supply continuity and extensive compliance documentation, mid-size firms balance flexibility with scale, and small biotech sponsors often prioritize agility, cost containment, and partner-led regulatory navigation.

Regional dynamics and capability clusters that influence partner selection, clinical trial access, regulatory alignment, and manufacturing localization across major geographies

Regional dynamics are reshaping where investments and partnerships materialize, reflecting differences in talent availability, regulatory environments, and infrastructure. In the Americas, a mature ecosystem combines established biomanufacturing capacity with a dense network of clinical sites and regulatory expertise, which supports high-complexity programs and rapid clinical translation. This region remains a hub for innovation, yet it also contends with higher operational costs and competitive demand for skilled manufacturing and quality personnel.

Europe, Middle East & Africa present a heterogeneous landscape where pockets of advanced capability coexist with markets that are rapidly scaling. European centers of excellence are notable for regulatory alignment across neighboring countries, well-developed GMP facilities, and a strong talent pipeline in biologics analytics. Emerging markets in the Middle East and Africa are increasingly attractive for clinical trials and certain manufacturing activities due to cost advantages, yet they require careful regulatory and logistical planning. Asia-Pacific is characterized by fast-growing manufacturing capacity, competitive cost structures, and substantial investments in cell and gene therapy capabilities. Several Asian markets are developing specialized clusters for biologics production and process innovation, which is driving increased collaboration with global sponsors and accelerating regional self-sufficiency for certain modalities.

Corporate capability narratives and competitive differentiation trends demonstrating how technical depth, regulatory expertise, and integrated service models define market leadership

Competitive positioning among companies operating in the biologics contract services space is increasingly defined by depth of technical capabilities, platform scalability, and the ability to deliver integrated services across development stages. Leading service providers differentiate through investments in advanced analytics, modular manufacturing platforms, and regulatory consulting teams capable of navigating multinational submissions. Equally important is the strength of quality systems and data governance practices, as clients demand transparent traceability and robust audit readiness across outsourced relationships.

Strategic partnerships, mergers, and targeted capacity expansions are common tactics companies use to fill capability gaps and to accelerate time-to-service for sponsors. Firms that cultivate cross-functional teams able to manage complex comparability exercises, implement process intensification, and support potency and safety testing stand to capture higher-value engagements. At the same time, nimble specialized providers retain appeal for early-stage sponsors seeking bespoke process development, rapid iteration, and close technical collaboration. Investors and business development teams are therefore evaluating not only physical assets but also intangible assets such as scientific talent, regulatory track record, and the flexibility of commercial terms.

Actionable recommendations for industry leaders to enhance supply resilience, accelerate technical capability convergence, and strengthen client alignment across biologics programs

Industry leaders should prioritize actions that strengthen supply resilience, accelerate technical convergence across modalities, and improve client-centric service delivery. First, embedding scenario planning for trade disruptions, raw material constraints, and regulatory changes into procurement and supply chain governance will reduce program vulnerability. This includes diversifying validated suppliers, creating redundancy across regions, and codifying change control pathways that anticipate regulatory engagement.

Second, investing in platform technologies that enable modular scale-up, digital batch records, and predictive maintenance will shorten development timelines and improve reproducibility. Training and talent development programs that bridge process engineering, analytical science, and regulatory strategy will increase organizational agility. Finally, adopting flexible commercial models-such as risk-sharing agreements and milestone-linked pricing-can align incentives between sponsors and providers, fostering long-term partnerships. Cultivating transparent communication channels and offering tailored regulatory support will enhance trust and position providers as strategic collaborators rather than transactional vendors.

Rigorous mixed-methods research methodology combining primary stakeholder interviews, regulatory and technical literature review, and triangulated qualitative analysis to ensure robust insights

The research synthesis presented here draws on a mixed-methods approach combining primary interviews with industry stakeholders, secondary review of technical and regulatory guidelines, and qualitative analysis of public filings and scientific literature. Primary engagement included structured discussions with manufacturing and clinical operations leaders, quality and regulatory experts, and R&D heads to capture firsthand perspectives on capability gaps, investment priorities, and partnership criteria. These interviews were complemented by a targeted review of regulatory guidance documents and peer-reviewed studies to ensure technical accuracy and to validate emerging trends.

Analytical rigor was maintained by triangulating findings across multiple sources and by applying scenario analysis to assess operational and strategic implications. Care was taken to anonymize proprietary inputs and to synthesize themes that reflect consensus and divergence among stakeholders. Limitations of the methodology are acknowledged, including the dynamic nature of policy and technological adoption and the potential for rapid shifts driven by clinical successes or supply chain disruptions. Nevertheless, the combination of qualitative insights and document analysis provides a robust foundation for the strategic observations and recommendations articulated in this report.

Concluding synthesis of strategic priorities and capability imperatives that will determine partner selection and program success in the evolving biologics services landscape

In summary, the biologics contract services ecosystem is maturing into a strategic, collaborative network where technical capability, regulatory acumen, and supply chain resilience determine successful program outcomes. Technological advances in cell and gene therapies, coupled with evolving regulatory expectations, are creating demand for integrated service models that span discovery through commercial manufacturing. Regional capability clusters and tariff-related trade considerations are reshaping sourcing decisions and prompting firms to adopt more sophisticated risk management and localization strategies.

For stakeholders across academia, biotech, and large pharmaceutical companies, the choice of partner increasingly reflects a balance between scientific expertise, operational reliability, and contractual flexibility. Providers that can demonstrate end-to-end capability, maintain high-quality data governance, and collaborate effectively on regulatory strategy will be best positioned to support complex biologics programs. Continued investment in talent, digital tools, and adaptable manufacturing platforms will be essential to meet the accelerating technical and commercial demands of the sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics CXO Services Market, by Service Model

  • 8.1. CDMO
    • 8.1.1. Analytical Testing
    • 8.1.2. Manufacturing
    • 8.1.3. Process Development
    • 8.1.4. Regulatory Consulting
  • 8.2. CMO
    • 8.2.1. Clinical Manufacturing
    • 8.2.2. Commercial Manufacturing
  • 8.3. CRO
    • 8.3.1. Clinical Trial Management
    • 8.3.2. Pharmacovigilance
    • 8.3.3. Preclinical Services

9. Biologics CXO Services Market, by Therapeutic Area

  • 9.1. Autoimmune
  • 9.2. Cardiology
  • 9.3. Infectious Diseases
  • 9.4. Neurology
  • 9.5. Oncology

10. Biologics CXO Services Market, by Clinical Stage

  • 10.1. Commercial
  • 10.2. Discovery
  • 10.3. Phase I
  • 10.4. Phase II
  • 10.5. Phase III
  • 10.6. Preclinical

11. Biologics CXO Services Market, by Application

  • 11.1. Cell Therapy
  • 11.2. Gene Therapy
  • 11.3. Monoclonal Antibodies
  • 11.4. Recombinant Proteins
  • 11.5. Vaccines

12. Biologics CXO Services Market, by End User

  • 12.1. Academia
  • 12.2. Biopharmaceutical Companies
  • 12.3. Research Institutions

13. Biologics CXO Services Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biologics CXO Services Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biologics CXO Services Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biologics CXO Services Market

17. China Biologics CXO Services Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AGC Biologics
  • 18.6. AGC Inc.
  • 18.7. Alvotech hf.
  • 18.8. BioVectra Inc.
  • 18.9. Boehringer Ingelheim International GmbH
  • 18.10. Catalent, Inc.
  • 18.11. Curia Global, Inc.
  • 18.12. Fujifilm Holdings Corporation
  • 18.13. Hikma Pharmaceuticals PLC
  • 18.14. Lonza Group AG
  • 18.15. Merck KGaA
  • 18.16. Novasep Holding SAS
  • 18.17. Patheon Biologics
  • 18.18. Piramal Pharma Solutions
  • 18.19. Polpharma Biologics
  • 18.20. PTC Bio, Inc.
  • 18.21. Recipharm AB
  • 18.22. Richter-Helm Biologics GmbH & Co. KG
  • 18.23. Samsung Biologics Co., Ltd.
  • 18.24. Sartorius AG
  • 18.25. Siegfried Holding AG
  • 18.26. Thermo Fisher Scientific Inc.
  • 18.27. Vetter Pharma International GmbH
  • 18.28. WuXi Biologics Inc.
  • 18.29. Xellia Pharmaceuticals A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICS CXO SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOLOGICS CXO SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ANALYTICAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ANALYTICAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ANALYTICAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY REGULATORY CONSULTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY REGULATORY CONSULTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY REGULATORY CONSULTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHARMACOVIGILANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHARMACOVIGILANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHARMACOVIGILANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ACADEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ACADEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY ACADEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 188. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 189. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 190. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 191. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 192. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. GCC BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 215. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 216. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 217. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 218. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 219. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. G7 BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 225. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 226. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 227. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 228. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 229. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. NATO BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL BIOLOGICS CXO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, BY SERVICE MODEL, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, BY CDMO, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, BY CMO, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, BY CRO, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA BIOLOGICS CXO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)